Skip to main content
. 2019 Aug 7;10:839. doi: 10.3389/fphar.2019.00839

Figure 3.

Figure 3

PGx-specific enriched markers other than that mentioned in PharmGKB. Disease ontology (left), FDA-approved drug (middle), and pharmacogenes (right) known (i.e., statistical association in clinical-genetics studies) to alter drug response or efficacy or lead to adverse drug response ( Supplementary Table 9 ).